Updated Jul 16, 2026
Farquhar John C.M. has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.04M.
John C.M. Farquhar is the Chief Executive Officer and a Director at HeartFlow, Inc., a medical technology company specializing in non-invasive solutions for diagnosing coronary artery disease. He has been involved in the company's operations and strategic direction.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-14 | HTFL | Heartflow, Inc. | S — Open-market sale [10b5-1] | 22.6K | $27.75 | $626K |
| 2026-06-26 | HTFL | Heartflow, Inc. | S — Open-market sale | 38.9K | $35.00 | $1.36M |
| 2026-06-12 | HTFL | Heartflow, Inc. | S — Open-market sale | 22.6K | $28.50 | $643K |
| 2026-05-13 | HTFL | Heartflow, Inc. | S — Open-market sale | 22.6K | $29.12 | $657K |
| 2026-05-08 | HTFL | Heartflow, Inc. | F — Tax withholding / forfeiture | 1.9K | $29.98 | $57K |
| 2026-05-08 | HTFL | Heartflow, Inc. | F — Tax withholding / forfeiture | 5.3K | $30.29 | $161K |
| 2026-04-14 | HTFL | Heartflow, Inc. | S — Open-market sale [10b5-1] | 22.6K | $26.72 | $603K |
| 2026-03-20 | HTFL | Heartflow, Inc. | S — Open-market sale [10b5-1] | 9.7K | $25.00 | $243K |
| 2026-03-12 | HTFL | Heartflow, Inc. | S — Open-market sale [10b5-1] | 12.8K | $22.66 | $291K |
| 2026-03-12 | HTFL | Heartflow, Inc. | A — Grant or award [10b5-1] | 2.6K | $16.15 | $42K |
| 2026-02-11 | HTFL | Heartflow, Inc. | S — Open-market sale [10b5-1] | 22.6K | $27.46 | $620K |
| 2026-02-11 | HTFL | Heartflow, Inc. | A — Grant or award [10b5-1] | 183.8K | $0.00 | |
| 2026-02-11 | HTFL | Heartflow, Inc. | F — Tax withholding / forfeiture [10b5-1] | 1.5K | $27.74 | $43K |
| 2025-08-07 | HTFL | Heartflow, Inc. | A — Grant or award | 59.9K | $0.00 |
John C.M. Farquhar is the Chief Executive Officer and a Director at HeartFlow, Inc., a medical technology company specializing in non-invasive solutions for diagnosing coronary artery disease. He has been involved in the company's operations and strategic direction.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($5.04M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Farquhar John C.M. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.